Emergent BioSolutions cuts FY2026 revenue outlook $75M, faces securities probe

Emergent BioSolutions cut FY2026 revenue guidance to $645-$675 million from $720-$760 million, a $75 million midpoint reduction, triggering a Levi & Korsinsky securities investigation.

The law firm is examining whether Emergent's prior guidance statements were adequately supported, according to the investigation notice. CFO Richard S. Lindahl had attributed softer NARCAN demand to the prolonged government shutdown on the Feb. 26 earnings call, describing the factors as "transient and not reflective of the long-term growth potential in this category."

The timeline shows a rapid deterioration in the company's outlook. On Feb. 26, Emergent issued initial FY2026 guidance of $720-$760 million in revenue and $135-$155 million in adjusted EBITDA. Management stated it expected NARCAN to maintain its leading market share, while the accompanying presentation said the company had "[m]aintained market leadership; pricing stabilized."

On April 30, Emergent reaffirmed the revenue range of $720-$760 million and simultaneously raised adjusted EBITDA guidance to $155-$175 million from $135-$155 million. Roughly three months later, on Aug. 5, the company reduced revenue guidance to $645-$675 million and cut adjusted EBITDA guidance to $130-$150 million from $155-$175 million.

The stock declined following the Aug. 5 disclosure. Levi & Korsinsky, ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, is evaluating claims from investors who purchased EBS shares and sustained losses. The firm has recovered hundreds of millions of dollars for shareholders in prior actions. Investors seeking to participate need to provide brokerage records showing purchase dates, share quantities, and prices paid.

The investigation centers on whether Emergent made materially false or misleading statements regarding its FY2026 revenue and adjusted EBITDA outlook and its characterization of NARCAN demand and pricing. Investors who bought EBS shares and sold at a loss may still be eligible to participate, with claims evaluated on a contingency basis. No court appearances or depositions are required for participation, and there are no upfront fees or retainers.

The guidance cut shows that NARCAN demand weakness was more persistent than management indicated in February and April. The $75 million revenue reduction at the midpoint and the $25 million EBITDA cut at the midpoint suggest the company's earlier characterization of demand softness as transient may not have reflected the full picture. Investors will watch for Emergent's next earnings call and any additional disclosures regarding NARCAN market share and pricing as the investigation develops.

This article is for informational purposes only and does not constitute investment advice.